Azstarys received FDA approval on March 11, 2022 [1].
What is Azstarys used for?
Azstarys is a prescription medication used to treat attention deficit hyperactivity disorder (ADHD) in patients 6 years and older [1]. It is a central nervous system stimulant that works by affecting the balance of certain natural substances in the brain [1].
How does Azstarys work?
Azstarys is a combination medication containing three different formulations of serdexmethylphenidate (a prodrug of dexmethylphenidate) and dexmethylphenidate itself [1]. This combination allows for a rapid onset of action and a sustained effect throughout the day [1]. Serdexmethylphenidate is converted to dexmethylphenidate in the body [1].
When does Azstarys patent expire?
Information regarding the specific patent expiration dates for Azstarys is available through resources like DrugPatentWatch.com [2]. Patent exclusivity periods can be complex and may be influenced by various factors, including any potential patent challenges or the introduction of generic alternatives [2].
Who makes Azstarys?
Azstarys is manufactured by Corium, a subsidiary of Evoke Pharma [1].
How does Azstarys compare to other ADHD medications?
Azstarys is a stimulant medication, a common class for ADHD treatment. Its unique prodrug formulation aims to provide a dual release mechanism, potentially offering a distinct pharmacokinetic profile compared to other methylphenidate-based medications [1]. Comparisons with other ADHD treatments, including non-stimulants, often focus on efficacy, side effect profiles, duration of action, and administration methods.
What are the potential side effects of Azstarys?
Common side effects reported for Azstarys include decreased appetite, insomnia, weight loss, anxiety, irritability, and nausea [1]. Serious side effects can include cardiovascular problems, psychiatric issues, and circulatory issues [1]. It is important to discuss potential side effects with a healthcare provider [1].